Thanks to Danny Lieberman for hosting Lior Shaltiel, PhD for a fascinating discussion about life, exosomes, regeneration of nerves and more on the Life Sciences Today podcast. Enjoy the full episode and hear about our vision for the future of regenerative medicine and the impact we hope to make with our first nanodrug, ExoPTEN. #spinalcordinjury #exosomes #innovation https://lnkd.in/d2caAfd8
NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
Biotechnology Research
Regenerate - Rewire - Recover
About us
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
- Website
-
https://nurexone.com
External link for NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Haifa
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
Haifa, IL
Employees at NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
-
Yossi Mograbi
-
Shulamit Levenberg
Professor at The Technion- Israel Institute of Technology
-
Sharon Soueid-Baumgarten
Senior Scientist at NurExone Biologic
-
Lior Shaltiel, PhD
Chief Executive Officer at NurExone Biologic (TSXV:NRX)(OTCQB:NRXBF)(FSE:J90) | Senior Lecturer (of the practice) Head of the BioMed-MBA program at…
Updates
-
🗞️ NurExone expands ExoPTEN’s potential to facial nerve regeneration, based on promising new data presented at ISEV 2025 in Vienna. These encouraging preclinical results mark a step towards a third nerve injury indication and market! https://lnkd.in/dP4hzFhy #biotech #regenerativemedicine #ISEV2025 #LevenbergLab
-
-
🚨 Exciting News from Vienna! NurExone Biologic is proud to be attending the International Society for Extracellular Vesicles Annual Meeting from April 24–27, 2025 in Vienna, Austria. We invite you to connect with our team and discover our groundbreaking ExoTherapy platform, advancing the future of regenerative medicine. Meet our brilliant scientists, Sharon Soueid-Baumgarten, PhD, Senior Scientist, and Isabelle Solomon, PhD, Head of Analytical Development, and learn more about our latest innovations in exosome-based therapeutics. Let’s discuss how we’re transforming possibilities in neural repair and beyond. See you there! 🌍💡 #ISEV2025 #Exosomes #RegenerativeMedicine #Biotech #NurExone #InnovationInScience #LifeSciences #ViennaEvents
-
-
NurExone welcomes biotech leader Jacob Licht to head U.S. operations and Exo-Top expansion! #scalingup https://lnkd.in/dGwQqrxq
-
-
Meet us this May at Invest at the Stuttgart Trade Fair Center in Germany! https://lnkd.in/gca62sV
-
-
NurExone Reports 2024 Financial Results and Corporate Milestones 💲 Closed April 2025 Offering: Raised C$2.3M to fuel U.S. expansion, preparation for uplisting to a major U.S. exchange, and upcoming development milestones. 👍 Product Pipeline: Accelerating IND filing for acute spinal cord injuries and promising preclinical data for optic nerve repair 🏭 R&D Expansion and Supply Chain Reinforcement: New lab facility and acquisition of a reliable source of critical raw materials 📃 Financial Update: Enhanced investments in R&D & G&A Read more: https://lnkd.in/dvmRsdVG #regenerativemedicine #exosomes #spinalcordinjury
-
Successfully closed a C$2.3M raise that will help: 🟦 Advance our clinical development 🟧 Drive U.S. expansion 🟨 Support our uplisting strategy Next steps: U.S. growth and clinical impact. #RealMomentum #ExoPTEN #Exosomes Read more: https://lnkd.in/dFYV_PDe
-
-
We’ll be at Invest 2025 in Stuttgart, Germany’s leading event for finance and investment professionals. If you’re attending, let’s connect and discuss the future of biotech innovation! #Invest2025 #Biotech #Innovation
-